<DOC>
	<DOCNO>NCT02106572</DOCNO>
	<brief_summary>The aim phase III study ass efficacy abnobaVISCUM® 900 compare Mitomycin C ( MMC ) monotherapy patient superficial bladder carcinoma evaluation time tumor recurrence . Secondary objective evaluate safety abnobaVISCUM® 900 , particular , compare toxicity two treatment . Another secondary objective treatment efficacy measure calculated prognosis recurrence progression 1 year , tumor grade case recurrence measurement Quality Life .</brief_summary>
	<brief_title>Therapeutic Instillation Mistletoe</brief_title>
	<detailed_description>This randomize , open-label , active-controlled , prospective , multinational Phase III confirmative study 2 treatment group adaptive design ( Bauer Köhne , 1994 ) . The study design compare efficacy treatment abnobaVISCUM® 900 Mitomycin C ( MMC ) . Patients completely resect superficial bladder carcinoma ( Stage Ta ) intermediate risk classification accord European Association Urology ( EAU , update 2013 ) one immediately post operative MMC 40 mg intravesical instillation eligible inclusion study . The study comprise screen period 4 week , treatment period 12 month abnobaVISCUM® 900 MMC follow-up period 12 month . Patients screen within 4 week transurethral resection bladder ( TURB ) immediately post operative MMC 40 mg intravesical instillation . A re-resection perform inclusion indicate . Every patient provide write informed consent study relate procedure perform .</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Mitomycin</mesh_term>
	<mesh_term>Mitomycins</mesh_term>
	<mesh_term>Viscum album peptide</mesh_term>
	<criteria>Signed date write informed consent data protection willingness participate comply study protocol prior studyrelated procedure Completely resect ( detrusor muscle TUR specimen present ) superficial bladder carcinoma ( Stage Ta ) classification intermediaterisk accord EAU ( update 2013 ) one immediately post operative intravesical MMC instillation 40 mg , complete reresection indicate Karnofsky Performance Status 50 % 100 % ( corresponding Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 2 ) Life expectancy ≥ 2 year time point study inclusion Normal renal liver function , normal cardiac hematology profile ( patient laboratory value slightly outside reference range may include , unless investigator considers abnormality clinically significant ) Female patient childbearing potential must negative pregnancy test ( βhuman chorionic gonadotropin test ) Screening . Pregnancy treatment period include 12 week last instillation exclude Locally infiltrative metastatic bladder tumor ( Stage T2 great ) , lowrisk Ta tumor ( primary , solitary , LG/G1 , &lt; 3 cm , CIS ) highrisk tumor accord EAU classification , update 2013 ( T1 ; HG/G3 ; CIS ; multiple recurrent large [ &gt; 3 cm ] Ta G1/G2 tumor [ condition must present point ] , presence upper urinary tract tumor lesion completely remove TURB Urinary tract infection , benign prostatic obstruction grade II III , neurogenic bladder , stress incontinence , bladder urethral diverticulum , fistulas urethral stenosis Patients acute systemic illness , inflammatory infection fever &gt; 38°C Patients previous recurrence superficial bladder cancer radiotherapy bladder intravesical treatment within last 6 month , patient previous mistletoe therapy Patients previous coexist malignancy CIS Patients previous concurrent therapy systemic chemo / immunotherapeutical treatment regimen , particular vinca alkaloid , bleomycine doxorubicine , patient treat pyroxidine hydrochloride ( vitamin B6 ) Untreated coagulation disorder inadequate anticoagulation therapy Leukocyte count &lt; 4,000/mm3 platelet count &lt; 100,000/mm3 Serum creatinine &gt; 1.7 mg/dL Patients know hypersensitivity excipients study medication ( monosodium phosphate , disodium phosphate , ascorbic acid ) Patients known hypersensitivity mistletoe product MMC Patients administer within 4week period Visit 1 experimental drug investigation Male patient plan father child sperm donation first administration study medication 3 month last administration study medication Male patient unwilling use barrier contraception ie , condom spermicide , day first administration study medication 12 week administration study medication Patients history alcohol / drug abuse Patients unable regularly observe , permit adequate followup compliance protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>superficial bladder cancer</keyword>
	<keyword>viscum album extract</keyword>
	<keyword>mistletoe extract</keyword>
	<keyword>abnobaVISCUM</keyword>
	<keyword>recurrence rate</keyword>
</DOC>